GelActive Spine

We are a spine startup company solving the problem of lower back pain with the first injectable spinal disc implant.  A dehydrated hydrogel is injected via needle into the decayed disc, the gel then increases in size 10x-15x, restoring volume, pressure, and water to a degenerated or dying disc which  restores  functionality of the disc.   

Currently there is no first line treatment for the millions of lower back pain sufferers that offers simultaneously a reduction in pain and a restoration of function in the damaged or diseased disc.  Current first line treatment includes an over reliance on opioids and steroids to mask the pain, with no real chance of restoration of function.  This creates a population of back pain sufferers diminished by either their back pain or the medication.   Patients will exist this way until the pain is intolerable and/or the DDD progresses to a point where  major surgery and metal ortho devices become the solution.

There is no other implant like ours and we believe it will become the new first line treatment for back pain and DDD.  (Our immediate market is the 10 million plus people on opioids and steroids)The procedure is simple, the cost is very low (compared to later-stage back procedures), and this procedure/product does not burn any bridges in terms of limiting future treatments.  This hydrogel is similar to disc tissue and can be removed easily with no lingering presence in the body.  

This product has been approved and used by doctors in Europe for 10 years but has never been commercialized in the US.   We believe the challenge is not a "proof of concept", because we know it is working in Europe.  The challenge is to secure funding for FDA trials in the US and to be prepared to market and distribute the product upon approval.  Part of the funding would go to revitalizing the European business which is underperforming due to a total lack of marketing and distribution.  We believe its very possible to dramatically increase  European sales which we can then utilize to complete the FDA study and reduce the need for further rounds of investment which means less dilution for our original investors.  We would love the opportunity to get on the phone or zoom call with anybody interested.  

Our two co-founders have decades of experience in finance, biotechnology, and start-ups    Investors will be offered a Convertible Note with a 20% discount to the Preferred, with a 5% interest rate per annum.